Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
HHS Quote, Financials, Valuation and Earnings
Last price:
$3.39
Seasonality move
:
5.12%
Day range:
$3.31 - $3.31
52-week range:
$2.33 - $5.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.15x
P/B ratio:
1.23x
Volume:
658
Avg. volume:
9.5K
1-year change:
-37.55%
Market cap:
$24.5M
Revenue:
$185.2M
EPS (TTM):
-$0.74
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Harte-Hanks, Inc. has 428.7% upside to fair value with a price target of -- per share.
HHS vs. S&P 500
-
Over the past 5 trading days, Harte-Hanks, Inc. has overperformed the S&P 500 by 1.66% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Harte-Hanks, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Harte-Hanks, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Harte-Hanks, Inc. reported revenues of $39.5M.
Earnings Growth
-
Harte-Hanks, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Harte-Hanks, Inc. reported earnings per share of -$0.31.
Enterprise value:
39.8M
EV / Invested capital:
0.96x
Price / LTM sales:
0.15x
EV / EBIT:
10.13x
EV / Revenue:
0.24x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
235.46x
Price / Operating cash flow:
144.52x
Enterprise value / EBITDA:
4.65x
Gross Profit (TTM):
$26.2M
Return On Assets:
-5.35%
Net Income Margin (TTM):
-3.27%
Return On Equity:
-25.63%
Return On Invested Capital:
-12.14%
Operating Margin:
2.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $196.8M | $187.6M | $166.8M | $47.6M | $39.5M | |
| Gross Profit | $29.8M | $30.8M | $26.2M | $8M | $6.2M | |
| Operating Income | $9.1M | $9.2M | $3.9M | $2.7M | $1M | |
| EBITDA | $13.1M | $13.5M | $8.6M | $3.8M | $2.3M | |
| Diluted EPS | $3.04 | -$4.11 | -$0.74 | $0.02 | -$0.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $82.5M | $80.6M | $62.2M | $53.8M | $48.7M | |
| Total Assets | $112.5M | $111.1M | $110.8M | $108.1M | $92.7M | |
| Current Liabilities | $42.4M | $45.8M | $38.7M | $36.9M | $33M | |
| Total Liabilities | $141.1M | $114.2M | $90.3M | $87.1M | $72.8M | |
| Total Equity | -$28.7M | -$3.1M | $20.5M | $21M | $19.9M | |
| Total Debt | $30.9M | $16.1M | $13.6M | $21.6M | $18.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $15.9M | -$2.7M | $2.1M | -$3.1M | $3.8M | |
| Cash From Investing | -$7.3M | -$4M | -$2M | -$1.9M | -$1M | |
| Cash From Financing | -$12.6M | -$372K | $561K | -$163K | -$55K | |
| Free Cash Flow | $14.4M | -$7.1M | $169K | -$5M | $2.8M | |
HHS
Sector
Market Cap
$24.5M
$51M
Price % of 52-Week High
59.21%
62.77%
Dividend Yield
0%
0%
Shareholder Yield
3.68%
1.13%
1-Year Price Total Return
-37.55%
-5.42%
Beta (5-Year)
-0.170
0.326
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.27
200-day SMA
Sell
Level
$3.86
Bollinger Bands (100)
Sell
Level
3.11 - 3.73
Chaikin Money Flow
Buy
Level
929.2K
20-day SMA
Sell
Level
$3.32
Relative Strength Index (RSI14)
Buy
Level
52.77
ADX Line
Buy
Level
12.49
Williams %R
Neutral
Level
-24.6197
50-day SMA
Buy
Level
$3.22
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.411)
Sell
CA Score
(Annual)
Level (-1.0989)
Buy
Beneish M-Score
(Annual)
Level (-3.6889)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.9903)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Harte-Hanks, Inc. is a global customer experience company operating in three business segments: Marketing Services, Customer Care, and Fulfillment & Logistics Services. The company's mission is to partner with clients to provide them with a robust customer-experience, or CX, strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract, and engage their customers. Its services include strategic planning, data strategy, performance analytics, creative development, and execution, technology enablement, marketing automation, B2B and B2C e-commerce, cross-channel customer care, and product, print, and mail fulfillment. The company was founded in 1923 and is headquartered in Chelmsford, MA.
Stock Forecast FAQ
In the current month, HHS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HHS average analyst price target in the past 3 months is --.
-
Where Will Harte-Hanks, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Harte-Hanks, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Harte-Hanks, Inc.?
Analysts are divided on their view about Harte-Hanks, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Harte-Hanks, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Harte-Hanks, Inc.'s Price Target?
The price target for Harte-Hanks, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HHS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Harte-Hanks, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HHS?
You can purchase shares of Harte-Hanks, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Harte-Hanks, Inc. shares.
-
What Is The Harte-Hanks, Inc. Share Price Today?
Harte-Hanks, Inc. was last trading at $3.39 per share. This represents the most recent stock quote for Harte-Hanks, Inc.. Yesterday, Harte-Hanks, Inc. closed at $3.31 per share.
-
How To Buy Harte-Hanks, Inc. Stock Online?
In order to purchase Harte-Hanks, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get HHS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HHS
Sector
P/E ratio
--
16.33x
PEG ratio
0.00x
0.00x
P/B ratio
1.23x
1.30x
Price / LTM sales
0.15x
0.85x
Growth Metrics
HHS
Sector
Revenue growth
-17.03%
1.07%
Earnings growth
-1705.73%
9.34%
Revenue (5-year growth)
-3.17%
1.1%
Earnings forecast
--
$0.05
Profitability
HHS
Sector
Profitability FY 2024
$30.4M
$109.7M
Return on invested capital
-12.14%
0.48%
Return on assets
-5.35%
-0.17%
Return on equity
-25.63%
1.42%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
9
Balance Sheet
HHS
Sector
Total cash
$6.5M
$72.3M
Short term investments
--
$24.7M
Total assets
$112.9M
$549.2M
Long term debt
$18.4M
$12.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
